financetom
Market
financetom
/
Market
/
Japan's Nikkei drifts sideways as more earnings, US CPI awaited
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Japan's Nikkei drifts sideways as more earnings, US CPI awaited
May 13, 2024 9:00 PM

TOKYO, May 14 (Reuters) - Japan's Nikkei share average

drifted sideways in a narrow range on Tuesday as investors

braced for more local corporate earnings results and the release

of all-important U.S. inflation figures the following day.

The market was also cautious over a weakening currency and

rising domestic bond yields amid speculation that the Bank of

Japan could soon take additional policy tightening steps.

The Nikkei entered the midday recess up 0.05% at

38,199.10, with 102 of its 225 components rising versus 123 that

fell. The broader Topix eased 0.04%.

Earnings produced some standout winners and losers,

including heavyweight startup investor SoftBank Group,

which added 1.78% to be among the Nikkei's biggest supports on

the day.

Furukawa Electric ( FUWAF ) surged almost 19% to pace

advancers after reporting financial results, while chemical

company Tosoh Corp ( TOSCF ) led decliners with a 7.25% slide.

Sony Group ( SONY ) was up 0.38% ahead of its earnings

announcement due later in the day.

"There are a lot of individual drivers, but unfortunately

none that give an overall direction to the market," said Kazuo

Kamitani, an equities strategist at Nomura Securities.

Kamitani predicted the Nikkei would range between the five-

and 25-day moving averages at around 38,170 and 38,450

respectively, with a slight downward bias.

Daiwa Securities ( DSECF ) was another notable loser,

dropping 6.78% on news that it would invest 51.9 billion yen

($331.78 million) in Aozora Bank ( AOZOF ), making it the biggest

shareholder. Aozora Bank ( AOZOF ) shares eased 0.4%.

Drugmaker Shionogi fell about 3% after saying its

COVID treatment pill failed in a trial to show a statistically

significant reduction of 15 common symptoms of the illness.

Peer Chugai Pharmaceutical ( CHGCF ) tumbled 4.69% following

a successful trial of a rival haemophilia treatment from Novo

Nordisk.

"Good data was expected, but these results appear to be at

the upper end of expectations," Jefferies analysts wrote in a

research note.

"No change to our bullish view of Chugai, but this news may

hurt sentiment."

($1 = 156.4300 yen)

(Reporting by Kevin Buckland; Editing by Subhranshu Sahu)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2025 - www.financetom.com All Rights Reserved